The aim of the authors was to evaluate the impact of diabetes, hypertension, cardiovascular disease, and the use of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) with the primary outcomes (1) COVID‐19 severity (including need for invasive mechanical ventilation or intensive care unit admission or O2 saturation less than90%) and (2) intrahospital mortality due to confirmed COVID‐19. This evidence concerns the gene ACE and COVID-19.